What was studied?
An enzyme assay and modeling compared BPC-157 with two designed hybrid peptides for acetylcholinesterase inhibition.
What did the researchers report?
The peptides showed competitive inhibition, with the modified analogs performing differently. Potency was substantially lower than that of established clinical inhibitors.
What are the limits?
An enzyme interaction does not demonstrate neurological benefit. Hybrid sequences are distinct molecules, and results do not support treating a catalog peptide as an Alzheimer therapy.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.